4.8 Article

A Series of Potent CREBBP Bromodomain Ligands Reveals an Induced-Fit Pocket Stabilized by a Cation-π Interaction

Journal

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Volume 53, Issue 24, Pages 6126-6130

Publisher

WILEY-V C H VERLAG GMBH
DOI: 10.1002/anie.201402750

Keywords

bromodomain; CREBBP; enzyme inhibitors; epigenetics; ligand discovery

Funding

  1. Pfizer Neusentis
  2. EPSRC
  3. SGC [1097737]
  4. AbbVie
  5. Boehringer Ingelheim
  6. Canada Foundation for Innovation
  7. Canadian Institutes for Health Research
  8. Genome Canada
  9. GlaxoSmithKline
  10. Janssen
  11. Lilly Canada
  12. Novartis Research Foundation
  13. Ontario Ministry of Economic Development and Innovation
  14. Pfizer
  15. Takeda
  16. Wellcome Trust [092809/Z/10/Z, 095751/Z/11/Z]
  17. Science Without Borders (CAPES)
  18. Wellcome Trust [095751/Z/11/Z] Funding Source: Wellcome Trust

Ask authors/readers for more resources

The benzoxazinone and dihydroquinoxalinone fragments were employed as novel acetyl lysine mimics in the development of CREBBP bromodomain ligands. While the benzoxazinone series showed low affinity for the CREBBP bromodomain, expansion of the dihydroquinoxalinone series resulted in the first potent inhibitors of a bromodomain outside the BET family. Structural and computational studies reveal that an internal hydrogen bond stabilizes the protein-bound conformation of the dihydroquinoxalinone series. The side chain of this series binds in an induced-fit pocket forming a cation-pi interaction with R1173 of CREBBP. The most potent compound inhibits binding of CREBBP to chromatin in U2OS cells.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available